title: Immune response to racotumomab in a child with relapsed neuroblastoma.
abstract: Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides, eliciting an immune response in a child with relapsed neuroblastoma expressing the NeuGcGM3 ganglioside.
authors.affiliation: Department of Hemato-Oncology, Pediatric Hospital Prof. Dr. Juan P. Garrahan Buenos Aires, Argentina.
authors.forename: C
authors.initials: C
authors.lastname: Sampor
authors.forename: M D
authors.initials: MD
authors.lastname: Guthmann
authors.forename: A
authors.initials: A
authors.lastname: Scursoni
authors.forename: W
authors.initials: W
authors.lastname: Cacciavillano
authors.forename: A
authors.initials: A
authors.lastname: Torbidoni
authors.forename: L
authors.initials: L
authors.lastname: Galluzzo
authors.forename: S
authors.initials: S
authors.lastname: Camarero
authors.forename: J
authors.initials: J
authors.lastname: Lopez
authors.forename: M T G
authors.initials: MT
authors.lastname: de Dávila
authors.forename: L
authors.initials: L
authors.lastname: Fainboim
authors.forename: G L
authors.initials: GL
authors.lastname: Chantada